Catalog No.
PAC90701
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Obinutuzumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Gazyva.
Specificity
The product is specific for Obinutuzumab. This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays.
Concentration
0.21 mg/ml
Purification
Purified by antigen affinity column.
Accession
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
For research use only. Not for human or drug use.
